Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has issued an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced a strategic partnership with Crescent Biopharma to develop and commercialize oncology therapeutics, including SKB105 and CR-001, for the treatment of solid tumors. This collaboration allows both companies to leverage their strengths, with Crescent gaining rights to SKB105 outside Greater China and Kelun-Biotech acquiring rights to CR-001 within Greater China. The partnership is expected to enhance Kelun-Biotech’s global market presence and strengthen its oncology pipeline, potentially leading to significant financial gains through milestone payments and royalties.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$545.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and commercialization of oncology therapeutics. The company is known for its innovative drug candidates, including antibody-drug conjugates and bispecific antibodies, aimed at treating solid tumors.
Average Trading Volume: 668,561
Technical Sentiment Signal: Buy
Current Market Cap: HK$102.2B
Find detailed analytics on 6990 stock on TipRanks’ Stock Analysis page.